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Abstract
Introduction: The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms
in the susceptibility to giant-cell arteritis (GCA).
Methods: In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients
and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C
(rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase
chain reaction, by using a predesigned TaqMan allele discrimination assay.
Results: No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18
-607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and
controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for
the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -
607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was
significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95).
In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297
C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-
1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an
additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was
1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an
OR of 3.7.
Conclusions: Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the
susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic
variants was observed.
Introduction
Giant cell, arteritis (GCA) is a large- and medium-sized
blood vessel systemic vasculitis characterized by the
granulomatous involvement of the aorta and especially
its cranial branches [1]. GCA is now considered the
most common systemic vasculitis in elderly individuals
from Western countries [2,3]. Dendritic cells localized at
the adventitia-media border of normal medium-sized
arteries play a critical role in the initiation of this vascu-
litis [4]. The inflammatory activity of vascular lesions in
GCA is mediated by adaptive immune responses, with
CD4 T cells undergoing clonal expansion in the vessel
wall and releasing interferon (IFN)-g [4]. In the experi-
mental mouse model of GCA, systemic administration
of ligands for Toll-like receptor (TLR)2 or TLR4 in
human artery-SCID chimeras led to differentiation of
adventitial dendritic cells into chemokine-producing
effector cells with high-level expression of both CD83
and CD86 and mediated T-cell recruitment through
release of interleukin (IL)-18 [4]. GCA is also known to
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be associated with upregulation of IFN-g, which is criti-
cally involved in modulating the process of intimal
hyperplasia, leading to the severe ischemic complications
observed in this vasculitis [5]. Interestingly, IFN-g activ-
ity is promoted by IL-18, a proinflammatory cytokine,
member of the IL-1 cytokine family, which has been
shown to exert innate and acquired immune responses
[6,7]. IL-18 is expressed by a wide range of immune
cells [8] and can mediate both Th1 and Th2 driven
immune responses [9,10]. Of potential implication in
GCA, IL-18 in combination with IL-12, induces IFN-g
production in Th1 cells, B cells, and natural killer cells,
promoting Th1-type immune responses [11,12]. How-
ever, IL-18 may also stimulate Th2 immune responses
in the absence of IL-12 [13,14].
GCA is a complex polygenic disease [15]. Besides a
strong association of GCA with genes that lie within the
major histocompatibility complex (MHC) [16-21], many
other studies have shown the implication of genetic var-
iants in key components of immune and inflammatory
pathways in GCA susceptibility or clinical expression of
this vasculitis [21-34].
IL18 gene is located on chromosome 11q22.2-22.3
[35] and several polymorphisms within the IL18 promo-
ter gene have been associated with different inflamma-
tory and autoimmune diseases [36-43].
An important step forward in our understanding of
the pathogenesis of autoimmune diseases may be to
establish the presence of shared mechanisms that may
lead to a variety of very different complex autoimmune
diseases. Taking all these considerations together, in this
study we sought to establish the potential role of three
polymorphisms (-137, -607, -1297) within the promoter
of the IL18 gene in the susceptibility to biopsy-proven
GCA.
Materials and methods
Patients
In total, 212 patients diagnosed with biopsy-proven GCA
and 405 controls were included in this study. All of the
patients fulfilled the 1990 American College of Rheuma-
tology criteria for the classification of GCA [44]. Inclusion
criteria [45] and clinical features of the patient population
were described previously [46]. Also, definitions for speci-
fic features of the disease, such as polymyalgia rheumatica
(PMR), visual ischemic complications, or other severe
ischemic manifestations, have been previously described
[47,48]. In all cases, biopsy-proven GCA patients were
initially treated with prednisone, 40-60 mg/day, for 3 to 4
weeks. Methyl-prednisolone boluses (1 g daily for 3 days)
followed by 60-mg prednisone/day for 3 to 4 weeks were
used in most patients who had visual ischemic complica-
tions or strokes. The prednisone dose was progressively
tapered until discontinuation. Apart from visual complica-
tions or strokes that were irreversible in some cases, other
typical features of the disease such as headache, asthenia,
jaw claudication, or PMR improved after corticosteroid
therapy. A decrease of erythrocyte sedimentation rate was
observed in all cases after the onset of corticosteroid
therapy.
Patients and controls are Caucasians, with at least two
previous generations born in the corresponding regions,
and were included in this study after written informed
consent. We obtained approval for the study from the
local ethical committees.
IL18 polymorphisms selection
Several variations within the IL18 gene promoter region
are responsible for changes in the transcription rate
[49,50]. In the present study, we selected two functional
IL18 promoter polymorphisms (IL18 -137 and -607),
which were suggested to alter the IL18 promoter activ-
ity. To investigate further into genetic variants within
the IL18 promoter region, we observed in the database
[51] a variant in this region that could have a potential
role in IL-18 expression (IL18-1297 or rs360719). We
also studied this polymorphism based on the minor
allele frequency and its ability to bind the transcription
factor Oct-1. Location of the polymorphisms site was
based on the GenBank Accession Nos. [Genbank:
AB015961] and [Genbank:BC007461] as the reference
sequence. Interestingly, we recently confirmed that the
IL18-1297 gene polymorphism has a functional associa-
tion with systemic lupus erythematosus [52].
IL18 genotyping methods
DNA was obtained from peripheral blood mononuclear
cells, by using standard methods. The genotyping of the
three IL18 polymorphisms was performed by using pre-
designed TaqMan SNP Genotyping Assays (Applied Bio-
systems, Foster City, CA), as previously described [52].
Statistical analysis
We used the c2 test for Hardy-Weinberg equilibrium
and statistical analysis to compare allelic and genotypic
distributions. Genotype distribution was assessed by
using the c2 test. Odds ratio (ORs) and 95% confidence
intervals (95% CIs) were calculated according to Woolf’s
method by using the Statcalc program (Epi Info 2002;
Centers for Disease Control and Prevention, Atlanta,
GA, USA). P values < 0.05 were considered statistically
significant. LD was calculated by using Haploview v 4.0.
A logistic regression model was used to estimate gene-
gene interaction between the IL18 and TLR4 SNPs and
for the additive effects of the three SNPs. Fisher’s Exact
test was used to test for the difference in IL18 and
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TLR4 -risk allele counts between Cases and Controls.
Logistic regression analyses were performed by using
the software STATA (v.10.1).
Results
IL18 gene polymorphisms are associated with
susceptibility to GCA
The case/control ratio was 1:2, approximately. The esti-
mated power of this study for an estimated OR between
1.5 and 2.0 was 77% to 99.5%.
No evidence of departure from Hardy-Weinberg equi-
librium was observed in controls.
Table 1 shows the allele and genotype frequencies of
the IL18 -137 G>C, -607 C>A, and -1,297 T>C poly-
morphisms in biopsy-proven GCA patients and healthy
subjects.
No significant association between the IL18 -137 G>C
and GCA was observed. However, when the IL18 -607
C>A was assessed, we found that the frequency of allele
A was significantly increased in biopsy-proven GCA
patients compared with controls (47.8% versus 40.9%,
respectively; P = 0.02; OR, 1.32; 95% CI, 1.04-1.69). It
was due to a significantly increased frequency of homo-
zygosity for the IL18 -607 A/A genotype in the group of
patients with biopsy-proven GCA compared with
controls (20.4% versus 13.8 in patients and controls,
respectively; IL18 -607 A/A homozygous versus IL18
-607 C/A plus IL18 -607 C/C: P = 0.04; OR, 1.59; 95%
CI, 1.02-2.46) (Table 1).
Interestingly, a significant association between biopsy-
proven GCA and the IL18-1297 T>C was also found. In
this regard, the IL18-1297 allele C frequency was signifi-
cantly increased in biopsy-proven GCA patients (30.7%)
compared with controls (23.0%) (P = 0.003; OR, 1.48;
95% CI, 1.13-1.95) (Table 1). Moreover, the genotype
distribution of the IL18-1297 T>C polymorphism dis-
closed statistically significant differences between
biopsy-proven GCA patients and controls (P = 0.011). It
was due to a reduced frequency of individuals carrying
the IL18-1297 T/T genotype in the group of biopsy-pro-
ven GCA patients (46.7%) compared with the controls
(58.5%). In this regard, an increased susceptibility to
GCA was observed in individuals carrying the IL18-1297
C/C or the IL18-1297 C/T genotypes (IL18-1297 C/C)
plus T/C genotypes versus T/T genotype in GCA
patients compared with controls: P = 0.005; OR, 1.61;
95% CI, 1.15-2.25). We did not perform a haplotype
analysis because the most associated SNP rs360719
(-1297) is not located in a haplotype block, but is a
singleton.
Table 1 IL18 gene polymorphisms in a series of biopsy-proven GCA and matched controls
IL18
Polymorphisms
GCA patients
Number (%)
Healthy controls
Number (%)
-137 (G->C) (rs187238) Number = 212 Number = 403 P value OR (95% CI)
G/G 106 (50.0) 224 (55.6) Reference -
G/C 94 (44.3) 159 (39.4) 0.20 1.25 (0.87-1.79)
C/C 12 (5.7) 20 (5.0) 0.53 1.27 (0.56-2.84)
G 306 (72.2) 607 (75.3) Reference -
C 118 (27.8) 199 (24.7) 0.23 1.18 (0.89-1.55)
-607 (C->A) (rs1946518)a Number = 212 Number = 405 P value OR (95% CI)
C/C 53 (24.9) 129 (31.9) Reference -
C/A 116 (54.7) 220 (54.3) 0.21 1.28 (0.85-1.94)
A/A 43 (20.4) 56 (13.8) 0.02 1.87 (1.09-3.21)
C 221 (52.2) 478 (59.1) Reference -
A 203 (47.8) 332 (40.9) 0.02 1.32 (1.04-1.69)
-1297 (T->C) (rs360719)b Number = 212 Number = 405 P value OR (95% CI)
T/T 99 (46.7) 237 (58.5) Reference -
T/C 96 (45.3) 150 (37.0) 0.02 1.53 (1.07-2.20)
C/C 17 (8.0) 18 (4.4) 0.02 2.26 (1.063-4.82)
T 294 (69.3) 624 (77.0) Reference -
C 130 (30.7) 186 (23.0) 0.003 1.48 (1.13-1.95)
aGenotype distribution for the IL18 -607 (C->A) polymorphism: P = 0.054.
bGenotype distribution for the IL18 -1297 (T->C) (rs360719): P = 0.011.
Genotype frequencies for the IL18 -607 (C->A) (rs1946518) polymorphism: IL18 -607 A/A homozygous versus IL18 -607 C/A plus IL18 -607 C/C: P = 0.04; OR, 1.59;
95% CI, 1.02-2.46.
Genotype frequencies for the IL18-1297 (T->C) (rs360719) polymorphism: IL18-1297 C/C plus IL18-1297 T/C genotypes compared to IL18-1297 T/T genotype:
P = 0.005; OR, 1.61; 95% CI, 1.15-2.25.
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IL18 gene polymorphisms are not associated with clinical
manifestation of GCA patients
In a further step, we stratified GCA patients according
to the presence of PMR, visual ischemic complications,
and severe ischemic manifestations. However, no signifi-
cant differences were observed when GCA patients
were compared according to the presence or absence of
these specific clinical features of the disease (data not
shown).
Additive effects of the IL18 and TLR4 risk alleles in GCA
We recently reported an association between the TLR4
Asp299Gly polymorphism and GCA in our population
[46]. In the present study, we investigated the potential
combined effect of the risk IL18 and TLR4 alleles on
GCA susceptibility by using an additive logistic regres-
sion model. The distribution of the different combina-
tions of IL18 and TLR4 risk alleles in GCA patients and
controls is shown in Additional file 1. The overall differ-
ence in risk allele counts between GCA patients and
controls was statistical significance, P = 0.01. We
observed an additive effect of risk alleles on susceptibil-
ity to GCA. Figure 1 shows the OR for GCA according
to the presence of one or two and three or more risk
alleles among these three genetic variants, by using the
individuals with zero risk allele as the reference group.
As shown in the figure, the risk of GCA increases as a
function of the number of risk alleles, in an additive
manner. Thus, the OR for GCA is 1.9 (CI, 1.1-2.3) for
carriers of one or two risk alleles, and 3.7 (CI, 1.9-7.2)
for carriers of three or more risk alleles.
Discussion
In the present study, we examined for the first time the
contribution of three polymorphisms in the promoter
region of the IL18 gene for the susceptibility to GCA.
Our results support a potential role of the IL18 -607
C>A (rs1946518) and the IL18-1297 T>C (rs360719)
gene polymorphisms in the predisposition to biopsy-
proven GCA. Individuals carrying the IL18 -607 A/A
showed an increased risk of having GCA compared with
controls. A protective effect against the development of
GCA was found in individuals carrying the IL18-1297
T/T genotype. In contrast, an increased risk of GCA
was observed in individuals carrying the IL18- 1297
allele C.
Proinflammatory cytokines play a major role in the
pathogenesis of GCA [53], a disease associated with a
high inflammatory response [54]. IL-18 is a proinflam-
matory cytokine that induces T-helper 1 differentiation
and has cytotoxic T-lymphocyte functions. IL-18 has
also emerged as a pivotal cytokine in different autoim-
mune diseases [55]. A number of functional polymorph-
isms within the proximal promoter of the IL18 gene
that may interfere with transcription-factor-binding sites
have been verified [49,50]. The implication of the IL18
-1297 T>C polymorphism in the susceptibility to GCA
also has functional relevance because recent data from
our group confirmed that the relative quantification of
mRNA performed in total RNA from 23 healthy indivi-
duals carrying different genotypes for IL18 -1297 T>C
(rs360719) polymorphism was associated with an
increased expression in individuals carrying the C allele
Figure 1 Combined effects of the risk alleles of (IL18 -607 and -1297) and TLR4 (Asp299Gly) on susceptibility to GCA. Linear regression
analysis showed an additive effect of the risk alleles of the IL18 and TLR4 on GCA susceptibility. The ORs with 95% CI are shown as a function of
number of risk alleles of GCA.
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(CC+CT versus TT) [52]. Interestingly, Nabili et al. [56]
reported and increased expression of IL18 in temporal
artery biopsies of GCA patients, with no correlation
with clinical manifestations or hematologic parameters.
All these data are in accordance with our results and
support a potential role of these gene variants in the
susceptibility to GCA but not in the phenotypic expres-
sion of this vasculitis.
It has been proposed that a variety of inflammatory
and autoimmune diseases may share common patho-
genic mechanisms. IL18 promoter gene polymorphisms
have been associated with several autoimmune diseases.
With respect to this, an association of the IL18 -137
G>C [rs187238] but not the IL18 -607 C>A (rs1946518)
gene polymorphism with susceptibility to type I diabetes
was reported in a study [39]. However, another study of
the same two promoter polymorphisms in patients with
type I diabetes showed an increased frequency of IL18
-607 CA genotype compared with control subjects, but
no significant difference in the IL18 -137 allele frequen-
cies [57]. No significant association was found when the
IL18 -137 G>C (rs187238) and the IL18 -607 C>A
(rs1946518) gene polymorphisms were studied in
patients with multiple sclerosis, Crohn disease, or
ulcerative colitis [50,58].
In keeping with the results derived from a study on
Spanish individuals diagnosed with rheumatoid arthritis
(RA) [59], in the present study, we did not find a signifi-
cant association between the IL18 -137 (rs187238) poly-
morphism and biopsy-proven GCA.
A protective effect mediated by the IL18 -607 A/A
genotype was observed in Asian patients with RA [43].
It was not the case for Spanish individuals with RA [59].
However, according to our results, an association exists
between biopsy-proven GCA and the IL18 -607
(rs1946518) gene polymorphism. Moreover, our data
show an additional association of biopsy-proven GCA
with IL18 -1297 T>C (rs360719).
Taken together, the different results in terms of dis-
ease susceptibility mediated by the IL18 gene poly-
morphisms in different autoimmune diseases support
the notion that different pathogenic mechanisms are
involved in the development of polygenic diseases.
Although our data show a clear association of these
polymorphisms with GCA susceptibility in the Spanish
population, further studies in other populations with dif-
ferent genetic backgrounds are needed to clarify fully
the implication of IL18 promoter polymorphisms in
GCA susceptibility. However, most genetic associations
reported in Spanish patients with GCA also have been
replicated in other populations, such as HLA-DRB1 in
North American [16,17], Danish [21], French [60], and
Swiss [61], and IL-6 promoter and eNOS polymorph-
isms, in Italians [24,28]. This evidence may indicate a
high reproducibility of the genetic associations with
GCA among different populations and that the potential
association with IL18 may be also found in other popu-
lations. Nevertheless, the lack of genome-wide associa-
tion studies or whole-genome-scan linkage studies in
GCA makes necessary an independent replication study
to confirm our results by using a population of a differ-
ent genetic background.
When we determined the joint effect of the risk alleles
of IL18 and TLR4, we observed a considerably increased
risk of GCA (OR, 3.7) for those 25% GCA patients who
carried three or more risk alleles compared with those
who carried none. Interestingly, this OR was higher
than that obtained for any IL18 or TLR4 SNPs individu-
ally (OR, 1.37 for IL18 -607; OR, 1.48 for IL18 -1297,
and OR, 1.65 for TLR4 +896 G allele). The additive
effect observed between IL18 and TLR4 suggests that
combining information from common risk polymorph-
isms could improve disease prediction. These observa-
tions, as well as the findings showing that IL18 and
TLR4 genetic variants are associated with other autoim-
mune diseases [33,39-41,50,52,62-64], support the pivo-
tal role of innate immunity in the development of
autoimmunity and GCA. Nevertheless, further studies in
other populations are required to validate our findings.
Conclusions
The present study shows for the first time that IL18
gene promoter polymorphisms are associated with sus-
ceptibility to biopsy-proven GCA. In addition, an addi-
tive effect between the risk IL18 and TLR4 alleles was
observed.
Additional file 1: Supplementary table. Distribution of IL18/TLR4
genotype combinations in GCA patients and controls.
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